---
aliases: [Health care, Healthcare sector, Medical sector, Healthcare services]
---
#sector #healthcare

# Healthcare

Overview of healthcare sector: pharma, biotech, medtech, and services.

---

## Market segments

| Segment | Key players | Dynamics |
|---------|-------------|----------|
| **Big Pharma** | Pfizer, J&J, Merck, Lilly, Novo Nordisk | Patent cliffs, GLP-1 boom |
| **Biotech** | Amgen, Gilead, Regeneron, Vertex | Innovation, M&A targets |
| **Health Insurance** | [[UnitedHealth]], [[CVS Health]], [[Cigna]], [[Humana]] | See [[Insurance]] sector |
| **Medtech** | Medtronic, Abbott, Boston Scientific | Device innovation |
| **Services** | HCA, UHS | Hospital systems |
| **Distributors** | McKesson, AmerisourceBergen, Cardinal | Drug distribution |

---

## Current themes (2025-2026)

### GLP-1 / Obesity drugs

| Company | Drug | Status |
|---------|------|--------|
| **Novo Nordisk** | Ozempic, Wegovy | Market leader |
| **Eli Lilly** | Mounjaro, Zepbound | Fast follower |
| Amgen | MariTide | Phase 2 |
| Pfizer | Danuglipron | Struggling |

**TAM:** $100B+ obesity market by 2030.

**Ripple effects:**
- Negative: Bariatric surgery, diabetes devices, junk food
- Positive: Drug manufacturers, injection devices

### Patent cliffs

| Company | Drug | Patent expiry | Revenue at risk |
|---------|------|---------------|-----------------|
| Merck | Keytruda | 2028 | ~$25B |
| AbbVie | Humira | 2023 (lost) | Biosimilar competition |
| Bristol-Myers | Opdivo | 2028 | ~$10B |

### AI in drug discovery

| Company | Approach |
|---------|----------|
| Recursion | AI-driven drug discovery |
| Insilico | Generative AI for molecules |
| Isomorphic Labs (Google) | AlphaFold applications |
| Big Pharma | Internal AI teams |

---

## Business models

| Model | Margin profile | Risk |
|-------|----------------|------|
| Big Pharma | High (70%+ gross) | Patent cliffs |
| Biotech | Variable | Binary outcomes |
| Medtech | Medium (60-70%) | Procedure volumes |
| Insurers | Low (MLR ~85%) | Medical costs |
| Distributors | Very low (~3%) | Volume-driven |

---

## Regulatory environment

| Agency | Role |
|--------|------|
| **FDA** | Drug/device approval |
| **CMS** | Medicare pricing, coverage |
| **FTC** | M&A review |

**IRA drug pricing:** Medicare negotiation for top drugs starting 2026.

---

## Investment themes

| Theme | Expression |
|-------|------------|
| GLP-1 dominance | Novo Nordisk, Eli Lilly |
| Biotech M&A | Large-cap pharma acquiring |
| AI drug discovery | Recursion, partnerships |
| Medicare Advantage | [[UnitedHealth]], [[Humana]] |
| Patent cliff losers | Avoid concentrated exposure |

---

## Key risks

| Risk | Impact |
|------|--------|
| **Drug pricing regulation** | Margin compression |
| **Patent expiry** | Revenue cliffs |
| **Clinical trial failures** | Biotech binary risk |
| **PBM scrutiny** | [[CVS Health]], [[Cigna]] |
| **GLP-1 competition** | First-mover advantages erode |

---

## Related

- [[Medical sciences primer]] — biology fundamentals for investing
- [[Biopharma]] — drug development detail
- [[Life Sciences]] — tools and diagnostics
- [[Insurance]] — health insurers detail
- [[UnitedHealth]] — largest insurer
- [[CVS Health]] — integrated model
- [[Humana]] — Medicare focus

## Sources

- TBD

*Updated 2026-01-08*
